McNeil label study shows understanding of allergy treatment indication, company says.
This article was originally published in The Tan Sheet
Executive Summary
NASALCROM OTC LABELING SUCCESSFULLY COMMUNICATES ALLERGY INDICATION to most of the respondents in a McNeil-sponsored label comprehension study, McNeil Medical Affairs Exec Director Anthony Temple, MD, told the members of the Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committees at an Oct. 10 joint meeting in Bethesda, Md. Temple presented the data in support of McNeil's OTC switch application for the Rx nasal solution. The committee recommended approval of OTC Nasalcrom for the treatment and prevention of allergy rhinitis.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning